Today’s H1’s highlight clinical development on track: dosing is due to start shortly in the large, pivotal Phase IIb trial of ReNeuron’s CTX therapy vs. placebo in Stroke (data expected early 2020); and a first read-out from the Phase I/II trial of the lead hPRC programme in Retinitis Pigmentosa (RP) remains expected in mid-2019. In our view, the re-positioning of ExPr0 represents a rational allocation of resource. We remain positive, and look forward to the outcome of on-going commercial discus ....
14 Dec 2018
H1 results: clinical development on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
H1 results: clinical development on track
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
14 Dec 2018 -
Author:
Dr Jens Lindqvist -
Pages:
3
Today’s H1’s highlight clinical development on track: dosing is due to start shortly in the large, pivotal Phase IIb trial of ReNeuron’s CTX therapy vs. placebo in Stroke (data expected early 2020); and a first read-out from the Phase I/II trial of the lead hPRC programme in Retinitis Pigmentosa (RP) remains expected in mid-2019. In our view, the re-positioning of ExPr0 represents a rational allocation of resource. We remain positive, and look forward to the outcome of on-going commercial discus ....